Skip to main content
. 2021 Feb 28;13(5):1011. doi: 10.3390/cancers13051011

Figure 3.

Figure 3

KAN0438757 effectively reduces glycolytic metabolites’ levels. (A) Glycolysis schematic representation. Red arrows mark the metabolites directly affected by KAN0438757 treatment in vitro. (B) LC-MS metabolomic analysis for HCT-116 cancer cells and HUVECs after 6h treatment with KAN0438757. (C) Seahorse analysis for oxygen consumption rate (OCR) evaluation performed with colorectal cancer cells and HUVECS upon 6 h treatment with KAN0438757. (C) Data is representative of three independent experiments. Data is ± SEM. * p < 0.05, ** p < 0.01 *** p < 0.001, **** p < 0.0001.